Search Results - "Erben, P"

Harmonization of molecular monitoring of CML therapy in Europe by Müller, M C, Cross, N C P, Erben, P, Schenk, T, Hanfstein, B, Ernst, T, Hehlmann, R, Branford, S, Saglio, G, Hochhaus, A

“…The high efficacy of the standard treatment of chronic myeloid leukemia (CML) with imatinib has prompted the need for accurate methods to monitor response at…”
Get full text

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) by Hanfstein, B, Müller, M C, Hehlmann, R, Erben, P, Lauseker, M, Fabarius, A, Schnittger, S, Haferlach, C, Göhring, G, Proetel, U, Kolb, H-J, Krause, S W, Hofmann, W-K, Schubert, J, Einsele, H, Dengler, J, Hänel, M, Falge, C, Kanz, L, Neubauer, A, Kneba, M, Stegelmann, F, Pfreundschuh, M, Waller, C F, Branford, S, Hughes, T P, Spiekermann, K, Baerlocher, G M, Pfirrmann, M, Hasford, J, Saußele, S, Hochhaus, A

“…In the face of competing first-line treatment options for CML, early prediction of prognosis on imatinib is desirable to assure favorable survival or otherwise…”
Get full text

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib by Hanfstein, B, Shlyakhto, V, Lauseker, M, Hehlmann, R, Saussele, S, Dietz, C, Erben, P, Fabarius, A, Proetel, U, Schnittger, S, Krause, S W, Schubert, J, Einsele, H, Hänel, M, Dengler, J, Falge, C, Kanz, L, Neubauer, A, Kneba, M, Stegelmann, F, Pfreundschuh, M, Waller, C F, Spiekermann, K, Baerlocher, G M, Pfirrmann, M, Hasford, J, Hofmann, W-K, Hochhaus, A, Müller, M C

“…Early assessment of response at 3 months of tyrosine kinase inhibitor treatment has become an important tool to predict favorable outcome. We sought to…”
Get full text

B-MYB—p53-related relevant regulator for the progression of clear cell renal cell carcinoma by Nientiedt, M., Müller, K., Nitschke, K., Erben, P., Steidler, A., Porubsky, S., Popovic, Z. V., Waldbillig, F., Mühlbauer, J., Kriegmair, M. C.

“…Purpose To investigate the mRNA expression of B-MYB and MDM2 together with their p53 relatedness in clear cell renal cell carcinoma (ccRCC). Methods Genes were…”
Get full text

Clinical relevance of gene expression in localized and metastatic prostate cancer exemplified by FABP5 by Nitschke, K., Erben, P., Waldbillig, F., Abdelhadi, A., Weis, C.-A., Gottschalt, M., Wahby, S., Nuhn, P., Boutros, M., Michel, M. S., von Hardenberg, J., Worst, T. S.

“…Purpose Fatty acid-binding protein 5 (FABP5), a transport protein for lipophilic molecules, has been proposed as protein marker in prostate cancer (PCa). The…”
Get full text

Radical cystectomy under continuous antiplatelet therapy with acetylsalicylic acid by Wessels, F., Kriegmair, M.C., Oehme, A., Rassweiler-Seyfried, M.C., Erben, P., Oberneder, R., Kriegmair, M., Ritter, M., Michel, M.S., Honeck, P.

“…Aim of this study was to analyse the perioperative outcome of patients undergoing radical cystectomy under continuous antiplatelet therapy with acetylsalicylic…”
Get full text

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer by Kriegmair, M.C., Wirtz, R.M., Worst, T.S., Breyer, J., Ritter, M., Keck, B., Boehmer, C., Otto, W., Eckstein, M., Weis, C.A., Hartmann, A., Bolenz, C., Erben, P.

“…INTRODUCTION: Gene expression analyses have identified similarities between bladder and breast cancer, where clinical risk stratification is based on Her2,…”
Get full text

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation by Metzgeroth, G, Erben, P, Martin, H, Mousset, S, Teichmann, M, Walz, C, Klippstein, T, Hochhaus, A, Cross, N C P, Hofmann, W-K, Reiter, A

Get full text

Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories by Müller, M C, Erben, P, Saglio, G, Gottardi, E, Nyvold, C G, Schenk, T, Ernst, T, Lauber, S, Kruth, J, Hehlmann, R, Hochhaus, A

“…Individualized PCR strategies hamper comparability of molecular results between different laboratories in several fields of medicine. To harmonize BCR-ABL mRNA…”
Get full text

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure by Agrawal, M, Hanfstein, B, Erben, P, Wolf, D, Ernst, T, Fabarius, A, Saussele, S, Purkayastha, D, Woodman, R C, Hofmann, W-K, Hehlmann, R, Hochhaus, A, Müller, M C

“…In the face of competing tyrosine kinase inhibitors (TKIs), identification of chronic myeloid leukemia (CML) patients expecting favorable response to…”
Get full text

Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma by METZGEROTH, G, WALZ, C, MÜLLER, M. C, BENEKE, H, MÜLLER, L, DEL VALLE, F, AULITZKY, W. E, WITTKOWSKY, G, SCHMITZ, N, SCHULTE, C, MULLER-HERMELINK, K, HODGES, E, SCORE, J, WHITTAKER, S. J, DIECKER, F, DÖHNER, H, SCHULD, P, HEHLMANN, R, HOCHHAUS, A, CROSS, N. C. P, REITER, A, SIEBERT, R, SCHNITTGER, S, HAFERLACH, C, POPP, H, HAFERLACH, T, ERBEN, P, MIX, J

“…The FIP1L1-PDGFRA fusion gene has been described in patients with eosinophilia-associated myeloproliferative disorders (Eos-MPD). Here, we report on seven…”
Get full text

Novel insights into a reputably irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy by Worst, T. S., Daskalova, K., Steidler, A., Berner-Leischner, K., Röth, R., Niesler, B., Weis, C.-A., Kriegmair, M. C., Erben, P., Pfalzgraf, D.

“…Purpose Until recently, tissue fibrosis—ultimately leading to permanent scaring—has been considered an irreversible process. However, recent findings indicate…”
Get full text

Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis by ERBEN, Philipp, GOSENCA, Darko, HAFERLACH, Claudia, CROSS, Nicholas C. P, HOCHHAUS, Andreas, REITER, Andreas, MÜLLER, Martin C, REINHARD, Jelena, SCORE, Joannah, DEL VALLE, Francesco, WALZ, Christoph, MIX, Jürgen, METZGEROTH, Georgia, ERNST, Thomas

“…Rapid identification of diverse fusion genes with involvement of PDGFRA or PDGFRB in eosinophilia-associated myeloproliferative neoplasms is essential for…”
Get full text

TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals by CHASE, Andrew, ERNST, Thomas, FIEBIG, Andreas, COLLINS, Andrew, GRAND, Francis, ERBEN, Philipp, REITER, Andreas, SCHREIBER, Stefan, CROSS, Nicholas C. P

“…The formation of fusion genes plays roles in both oncogenesis and evolution by facilitating the acquisition of novel functions. Here we describe the first…”
Get full text

Molecular Characterisation of Urothelial Bladder Cancer: Will it Improve Patient Care? by Erben, P, Hartmann, A, Bolenz, C

“…Urothelial bladder cancer is characterised by high recurrence and progression rates despite multimodal treatment. Only slight improvements have been achieved…”
Get more information

The molecular anatomy of the FIP1L1-PDGFRA fusion gene by Walz, C, Score, J, Mix, J, Cilloni, D, Roche-Lestienne, C, Yeh, R-F, Wiemels, J L, Ottaviani, E, Erben, P, Hochhaus, A, Baccarani, M, Grimwade, D, Preudhomme, C, Apperley, J, Martinelli, G, Saglio, G, Cross, N C P, Reiter, A

“…The FIP1L1-PDGFRA fusion gene is a recurrent molecular abnormality in patients with eosinophilia-associated myeloproliferative neoplasms. We characterized…”
Get full text

Prognostic role of FGFR alterations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second line setting by Roghmann, F., Wirtz, R., Santiago-Walker, A., Jarczyk, J., Kriegmair, M.C., Worst, T.S., Sikic, D., Wach, S., Taubert, H., Weyerer, V., Stoehr, R., Tully, K., Zengerling, F., Bolenz, C., Breyer, J., Burger, M., Porubsky, S., Hartmann, A., Erben, P., Eckstein, M., Jütte, H.

Get full text

Omacetaxine mepesuccinate prevents cytokine-dependent resistance to nilotinib in vitro: potential role of the common β-subunit c of cytokine receptors by Klag, T, Härtel, N, Erben, P, Schwaab, J, Schnetzke, U, Schenk, T, Hochhaus, A, La Rosée, P

“…Overcoming resistance against BCR-ABL-inhibitors in chronic myeloid leukemia (CML) is central to prevent progression to advanced phase disease. Kinase…”
Get full text

Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/β expression in squamous cell carcinoma of the head and neck in vitro by SCHULTZ, J. D, ROTUNNO, S, SAUTER, A, RIEDEL, F, ANDERS, C, ERBEN, P, HOFHEINZ, R. D, FABER, A, THORN, C, SOMMER, J. U, HÖRMANN, K

Get full text

Expression of transketolase-like gene 1 (TKTL1) depends on disease phase in patients with chronic myeloid leukaemia (CML) by Philipp, M., Schwaab, J., Dietz, C. T., Hanfstein, B., Kalmanti, L., Munjal, U., Mossner, M., Nowak, D., Seifarth, W., Hofmann, W. K., Hochhaus, A., Müller, M. C., Erben, P.

“…Purpose Overexpression of transketolase - like gene 1 ( TKTL1 ) on RNA and protein level has been linked to tumour progression, metastasis and unfavourable…”
Get full text